Regencell Bioscience (RGC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$11.7M

Net income growth (year over year)

−226.49%

Net margin

—

Return on equity

−128.52%

EPS (trailing twelve months)

−$0.02

Book value per share

$0.03

P/E (trailing twelve months)

—

Price to book

263.37

Debt to assets

9.37%

Payout ratio

—

Dividend yield

—

Company profile

Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.

• How do I buy stock in Regencell Bioscience (RGC)?

  RGC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.